B2B SaaS in Pharma and Life Sciences

September 19, 2024
by a searcher from INSEAD in Praha, Česko
I am signing LOI with a Prague based B2B SaaS company.
~40 clients primarily in pharma and life science industries globally (mostly EU, growing in India, some of them big names).
Modular product loved by users, 50% implementation time and cost vs. competition.
Impressive TAM with solid organic growth. Potential to expand regionally and into new industries (FMCG, Energy)
$1.6m ARR, +30% p.a., $700k EBITDA. Low churn.
Price ~3x multiple. Seller financing available.
Seeking equity investors who could help with expansion, primarily in the US, EU and India.
from Stanford University in Amsterdam, Netherlands
from Northwestern University in Chicago, IL, USA